Clinical trial Recruiting at 1 site Observational Ages 75 to 100

Evaluating the safety and effectiveness of Onyx stents in elderly patients with coronary artery disease

Official title: Safety and Efficacy of 1-month Dual Antiplatelet Therapy in High Bleeding and Ischemic Risk Elderly Patients With Coronary Artery Disease After Implantation of Zotarolimus-eluting Coronary Stent System (Onyx Family, Medtronic, Minneapolis, MN); A Multicenter, Prospective, Observational Study

Run by Pusan National University Yangsan Hospital · NCT06577896 · Data updated 2026-11-12

This study is testing if switching from two blood-thinning medications to one after using Onyx stents helps elderly patients with heart disease stay safe and healthy over a year.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages75 Years to 100 Years
SexAll
Enrollment500 (estimated)
SponsorPusan National University Yangsan Hospital
Academic / other
Locations1 site (Yangsan, Gyeongsangnam-do)
StatusRecruiting
StartedJune 9, 2022
Main results expectedJanuary 31, 2026
Study endsDecember 31, 2026
Registry record updatedSeptember 19, 2024
Trial IDNCT06577896 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are elderly patients aged 75 years or older who have undergone coronary artery procedures with Onyx family stents and are able to take antiplatelet medications.

Probably not a fit

Patients with known hypersensitivity to antiplatelet medications or those with active bleeding conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on elderly patients aged 75 years or older who are undergoing percutaneous coronary intervention with Onyx family drug-eluting stents. It aims to observe the safety and efficacy of transitioning from dual antiplatelet therapy to single therapy after one month of dual therapy. The study will monitor these patients for one year following the procedure to assess outcomes related to myocardial ischemia and coronary artery stenosis. The goal is to determine the best antiplatelet strategy for this vulnerable population.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment protocols for elderly patients with coronary artery disease, potentially reducing the risk of complications associated with prolonged dual antiplatelet therapy.

How similar studies have gone: While there have been studies on dual antiplatelet therapy, this specific approach focusing on elderly patients with Onyx stents is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged 75 or more.
* Eligible for interventional procedures.
* Evidence of myocardial ischemia or coronary artery stenosis ≥ 50%.
* Able to take antiplatelets for at least 1 months after the procedure.
* Patients who underwent coronary artery procedures with ZES (Medtronic, Minneapolis, MN, Onyx™ family) stent.

Exclusion Criteria:

* The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, zotarolimus, and contrast media (patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[eg, rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled).
* Patients with active pathologic bleeding.
* Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia).
* Noncardiac comorbid conditions are present with life expectancy \<1 year or that may result in protocol noncompliance (per site investigator\'s medical judgment).
* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.

Where it's running

  • Pusan National University Yangsan Hospital
    Yangsan, Gyeongsangnam-do, South Korea
    Recruiting

Study contacts

  • Principal investigator: Min Ku Chon, MD,PhD — Pusan National University Yangsan Hospital
  • Study coordinator: Min Ku Chon, MD,PhD
  • Email: chonmingu@gmail.com
  • Phone: 82-10-2562-6258

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.